Suppr超能文献

肾上腺功能减退的动态评估

Dynamic evaluation of adrenal hypofunction.

作者信息

Nieman L K

机构信息

Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1583, USA.

出版信息

J Endocrinol Invest. 2003;26(7 Suppl):74-82.

Abstract

The diagnosis of adrenal hypofunction is suggested by clinical features and confirmed by biochemical testing. The characteristic features of acute primary adrenal insufficiency include orthostatic hypotension, fever, and hypoglycemia. By contrast, patients with chronic primary adrenal insufficiency have a longer history of malaise, as well as fatigue, anorexia, diarrhea, weight loss, joint and back pain, and darkening of the skin. While the clinical presentation of secondary adrenal insufficiency is similar to that of primary adrenal insufficiency, there is no hyperpigmentation, and hypotension and orthostasis are less pronounced. As a result, patients often present with vague, non-specific symptoms and the diagnosis may not be entertained. There is considerable debate regarding the best dynamic test for the diagnosis of adrenal hypofunction. Optimally, a screening test would be economic, convenient and safe. It would have high sensitivity and specificity based on consensus criteria for interpretation. Unfortunately, to date no test meets all of these criteria. Measurement of basal cortisol is an inexpensive and convenient screening test that can include (< 3 microg/dl; 83 nmol/l) or exclude (> 19 microg/dl; 524 nmol/l) adrenal insufficiency. However, most patients will have intermediate values and will require dynamic testing. This review discusses the use of metyrapone, insulin, CRH and synthetic ACTH 1-24 as provocative agents for cortisol secretion. Although the insulin and metyrapone stimulation tests have the advantage of testing the entire hypothalamic-pituitary-adrenal axis, they are cumbersome and carry more risk than the other tests. The 250 microg ACTH test works well to identify primary adrenal hypofunction, but can only detect secondary adrenal hypofunction when there is sufficient time for the glands to atrophy because of reduced endogenous ACTH stimulation. The 1 microg ACTH test has been advocated in the setting of possible secondary adrenal insufficiency, but its widespread use has been mitigated by the lack of a commercial preparation of this small dose and controversy regarding diagnostic criteria. Ultimately, the choice of test should be individualized for each patient, with knowledge of the available reference assays and the vagaries of each test.

摘要

肾上腺功能减退的诊断依据临床特征提示,并通过生化检测得以确诊。急性原发性肾上腺功能不全的特征性表现包括体位性低血压、发热和低血糖。相比之下,慢性原发性肾上腺功能不全患者有更长时间的不适病史,以及疲劳、厌食、腹泻、体重减轻、关节和背部疼痛,皮肤色素沉着加深。虽然继发性肾上腺功能不全的临床表现与原发性肾上腺功能不全相似,但无色素沉着过度,低血压和体位性低血压也不那么明显。因此,患者常表现出模糊、非特异性的症状,诊断可能不被考虑。关于诊断肾上腺功能减退的最佳动态试验存在相当大的争议。理想情况下,筛查试验应经济、方便且安全。根据共识性解释标准,它应具有高敏感性和特异性。不幸的是,迄今为止没有一种试验能满足所有这些标准。基础皮质醇的测定是一种廉价且方便的筛查试验,其结果可提示(<3μg/dl;83nmol/l)或排除(>19μg/dl;524nmol/l)肾上腺功能不全。然而,大多数患者的值处于中间范围,需要进行动态试验。本综述讨论了使用美替拉酮、胰岛素、促肾上腺皮质激素释放激素(CRH)和合成促肾上腺皮质激素1-24作为刺激皮质醇分泌的药物。虽然胰岛素和美替拉酮刺激试验具有检测整个下丘脑-垂体-肾上腺轴的优势,但它们操作繁琐,且比其他试验风险更大。250μg促肾上腺皮质激素试验在识别原发性肾上腺功能减退方面效果良好,但只有当由于内源性促肾上腺皮质激素刺激减少,腺体有足够时间萎缩时,才能检测出继发性肾上腺功能减退。1μg促肾上腺皮质激素试验已在可能存在继发性肾上腺功能不全的情况下被提倡,但由于缺乏这种小剂量的商业制剂以及诊断标准存在争议,其广泛应用受到了限制。最终,试验的选择应根据每个患者的具体情况个体化,同时要了解可用的参考检测方法以及每种试验的不确定性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验